Status:

COMPLETED

Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation

Lead Sponsor:

University Hospital Tuebingen

Collaborating Sponsors:

Federal Ministry of Health, Germany

Institute of Clinical Epidemiology and applied Biometry, University Tuebingen, Germany

Conditions:

Major Depressive Disorder

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

This is a randomized, double-blind, sham-controlled multicenter clinical trial. The aim is to provide evidence for efficacy of TBS in the treatment of patients with major depression. There will be a d...

Eligibility Criteria

Inclusion

  • moderate or severe unipolar depression diagnosed according to criteria of Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)
  • duration of the current episode must be ≥ 6 weeks and ≤ 2 years
  • HDRS17 ≥ 18
  • mild to moderate treatment resistance according to the Antidepressant Treatment History Form \[ATHF-SF\]. Treatment resistance is defined as having failed at least one but no more than three adequate antidepressant treatments in this episode
  • stable antidepressive medication 4 weeks before treatment or no antidepressive treatment
  • no further relevant psychiatric axis-I and/or axis-II disorder except for anxiety disorders (according to DSM-5 and SCID-5-PD)
  • no comorbid psychotic symptoms
  • ability to give consent

Exclusion

  • acute suicidality (MADRS item 10 score \> 4)
  • antiepileptic drugs and/or benzodiazepines corresponding to \> 1mg lorazepam / day
  • history of brain surgery, significant and clinically relevant brain malformation or neoplasm, head injury, stroke, dementia or other neurodegenerative disorder
  • history of seizures
  • previous rTMS treatment
  • lifetime history of non-response to adequate electroconvulsive therapy (minimum of eight treatments)
  • deep brain stimulation
  • cardiac pacemakers, intracranial implant, or metal in the cranium
  • substance dependence or abuse in the past 3 months (with the exception of tobacco)
  • severe somatic comorbidity as judged by the study physician
  • pregnancy

Key Trial Info

Start Date :

September 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 31 2025

Estimated Enrollment :

238 Patients enrolled

Trial Details

Trial ID

NCT04392947

Start Date

September 29 2020

End Date

July 31 2025

Last Update

September 17 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, Bezirkskrankenhaus Augsburg

Augsburg, Germany, 86156

2

University of Leipzig, Dept. Psychiatry and Psychotherapy

Leipzig, Germany

3

University of Munich

Munich, Germany, 80336

4

University of Regensburg, Dept. Psychiatry and Psychotherapy

Regensburg, Germany, 93053